Zdrowie i gospodarka · 11/04/1994

Prospective Grant of Exclusive License: Use of Monoclonal Antibodies Having Binding Specificity to Tag-72 and Human Carcinomas for Targeting Tumor Necrosis Factor and Phospholipase A2 Activating Protein as Cancer Therapeutics

The National Institutes of Health (NIH) is contemplating the grant of a limited field of use exclusive license to Enzon, Inc. for the use of monoclonal antibodies in cancer therapeutics.